Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial-Reference-Cited by-同舟云学术

Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial

Published:2018-07-16 Issue:10 Volume:20 Page:2408-2415
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Han Kyung-Ah¹,Chon Suk²,Chung Choon Hee³,Lim Soo⁴^ORCID,Lee Kwan-Woo⁵,Baik SeiHyun⁶,Jung Chang Hee⁷^ORCID,Kim Dong-Sun⁸,Park Kyong Soo⁹,Yoon Kun-Ho¹⁰,Lee In-Kyu¹¹,Cha Bong-Soo¹²^ORCID,Sakatani Taishi¹³,Park Sumi¹⁴,Lee Moon-Kyu¹⁵^ORCID

Affiliation:

1. Nowon Eulji Medical Center; Eulji University; Seoul Korea

2. Kyung Hee University Hospital; Seoul Korea

3. Yonsei University Wonju Severance Christian Hospital; Gangwon Korea

4. Seoul National University College of Medicine and Seoul National University Bundang Hospital; Seongnam Korea

5. Ajou University Hospital; Suwon-si Korea

6. Korea University Guro Hospital; Seoul Korea

7. Department of Endocrinology and Metabolism, Asan Medical Center; University of Ulsan College of Medicine; Seoul Korea

8. Department of Endocrinology and Metabolism; Hanyang University Hospital; Seoul Korea

9. Department of Internal Medicine; Seoul National University College of Medicine; Seoul Korea

10. Department of Endocrinology and Metabolism, Seoul St. Mary's Hospital; Catholic University Medical College; Seoul Korea

11. Department of Internal Medicine; Kyungpook National University Hospital; Daegu Korea

12. Department of Internal Medicine; Yonsei University Severance Hospital; Seoul Korea

13. Biostatistics Group, Japan-Asia Data Science, Development; Astellas Pharma Inc.; Tokyo Japan

14. Clinical Research Team, Development Department; Astellas Pharma Korea, Inc.; Seoul Korea

15. Department of Medicine, Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Korea

Funder

Astellas Pharma

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13394/fullpdf

Reference25 articles.

1. International Diabetes Federation 2017 www.idf.org/managing-type2-diabetes

2. Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association;Ko;Diabetes Metab J,2017

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials;Expert Opinion on Pharmacotherapy;2024-05-02

2. Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis;BMC Endocrine Disorders;2024-04-24

3. Comparative efficacy and safety of sodium–glucose cotransporter 2 inhibitors for renal outcomes in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis;Renal Failure;2023-09-19

4. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials;Frontiers in Endocrinology;2023-08-28

5. Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials;Frontiers in Pharmacology;2023-06-13